Global Women Health Therapeutics Market 2022-2028

Description

List of Tables

Global Women Health Therapeutics Market Size, Share & Trends Analysis Report by Type (Infection, Pregnancy, and Oncology), and by End-User (Hospitals and Clinics and Ambulatory Centers) Forecast Period (2022-2028)

The global women health therapeutics market is anticipated to grow at a considerable CAGR of 5.3% during the forecast period. One of the core factors contributing to the growth of the market includes the growing demand forhealth diagnostics and therapeutics across the globe.This is due to the growing burden of breast cancer. Breast cancer is the most common cancer in women in the US. About 30% (or 1 in 3) of all new femalesare diagnosed with cancers each year. According to the American Cancer Society of the US, in 2022, about 287,850 new cases of invasive breast cancer were diagnosed in women. Furthermore, the rising several R&D and drug approval activities by key market players globally is another factor bolstering the market growth. For instance, inOctober 2021, the FDA approved a new drug for one type of breast cancer. The drug, named abemaciclib underthe brand name Verzenio, was approved for patients with the HR+, HER2-early breast cancer, which makes up 70% of all breast cancers.

The global women health therapeuticsmarket is segmented based on the type and end-user. Based on type, the market is classified into infection, pregnancy, and oncology. The oncology segment is further augmented into cervical cancer, uterine cancer, ovarian cancer, and vaginal &vular. Based on the end-user, the market is segmented into hospitals and clinics, and ambulatory centers. The above-mentioned segments can be customized as per the requirements.

Geographically the global women health therapeuticsmarket is segmented into North America, Europe, Asia Pacific, and the Rest of the World.North America is expected to hold a significant share in the global market due to the growing focus onwomen health and the increasing prevalence of chronic disorders such as breast and ovarian cancer.According to Globocan, in 2020, around 2.26 million new breast cancer cases were reported in females, accounting for around 11.7% of the total cancer cases. Severalproduct launches areanother key factor to drive the growth of the market across the region. For instance, in January 2021, Roche launched its CE-IVD-approved automated digital pathology algorithms, uPath HER2 (4B5) imageanalysis, and uPath HER2 Dual ISH image analysis for breast cancer.

The major companies serving the global women health therapeutics market include Novartis AG, Abbott Laboratories, Inc., Pfizer Inc., Eli Lilly and Co., Bayer AG, Merck KGaA, Novo Nordisk A/S, F. Hoffmann-La Roche Ltd, and others. The market players are considerably contributing to the market growth by the adoption of various strategies including mergers andacquisitions, collaborations, funding, and new product launches, to stay competitive in the market. For instance, in September 2021, Abbott acquired Walk Vascular LLC, a commercial-stage medical device firm with a minimally hostile mechanical aspiration thrombectomy system for the elimination of peripheral blood clots.

Research Methodology

The market study of the global women health therapeutics market is incorporated by extensive primary and secondary research conducted by the research team at OMR. Secondary research has been conducted to refine the available data to breakdown the market into various segments, and derive the total market size, market forecast, and growth rate. Different approaches have been worked on to derive the market value and market growth rate. Our team collects facts and data related to the market from different geography to provide a better regional outlook. In the report, the country-level analysis is provided by analyzing various regional players, regional tax laws and policies, consumer behavior, and macroeconomic factors. Numbers extracted from secondary research have been authenticated by conducting proper primary research. It includes tracking down key people from the industry and interviewing them to validate the data. This enables our analyst to derive the closest possible figures without any major deviations in the actual number. Our analysts try to contact as many executives, managers, key opinion leaders, and industry experts. Primary research brings authenticity to our reports.

Secondary Sources Include

Financial reports of companies involved in the market.
Whitepapers, research papers, and news blogs.
Company websites and their product catalog.

The report provides an in-depth analysis of the market size, and intended quality of the service preferred by consumers. The report will serve as a source for a 360-degree analysis of the market thoroughly integrating different models.

Market Segmentation

1. Global Women Health Therapeutics Market Research and Analysis by Type.

2. Global Women Health Therapeutics Market Research and Analysis by End-User.

The Report Covers

Comprehensive research methodology of the global women health therapeutics market.
This report also includes a detailed and extensive market overview with key analyst insights.
An exhaustive analysis of macro and micro factors influencing the market guided by key recommendations.
Analysis of regional regulations and other government policies impacting the global women health therapeuticsmarket.
Insights about market determinants that are stimulating the global women health therapeuticsmarket.
Detailed and extensive market segments with the regional distribution of forecasted revenues.
Extensive profiles and recent developments of market players.

Product Code: MD-1229

Category- Pharmaceuticals

1. Report Summary

Current Industry Analysis and Growth Potential Outlook
Impact of COVID-19 on the Global Women Health Therapeutics Market
Recovery Scenario of Global Women Health Therapeutics Market
1.1. Research Methods and Tools
1.2. Market Breakdown
- 1.2.1. By Segments
- 1.2.2. By Region

2. Market Overview and Insights

2.1. Scope of the Report
2.2. Analyst Insight & Current Market Trends
- 2.2.1. Key Findings
- 2.2.2. Recommendations
- 2.2.3. Conclusion

3. Competitive Landscape

3.1. Key Company Analysis
- 3.1.1. Abbott Laboratories, Inc.
  - 3.1.1.1. Overview
  - 3.1.1.2. Financial Analysis
  - 3.1.1.3. SWOT Analysis
  - 3.1.1.4. Recent Developments
- 3.1.2. Bayer AG
  - 3.1.2.1. Overview
  - 3.1.2.2. Financial Analysis
  - 3.1.2.3. SWOT Analysis
  - 3.1.2.4. Recent Developments
- 3.1.3. Eli Lilly and Co.
  - 3.1.3.1. Overview
  - 3.1.3.2. Financial Analysis
  - 3.1.3.3. SWOT Analysis
  - 3.1.3.4. Recent Developments
- 3.1.4. F. Hoffmann-La Roche LTD.
  - 3.1.4.1. Overview
  - 3.1.4.2. Financial Analysis
  - 3.1.4.3. SWOT Analysis
  - 3.1.4.4. Recent Developments
- 3.1.5. Novartis AG
  - 3.1.5.1. Overview
  - 3.1.5.2. Financial Analysis
  - 3.1.5.3. SWOT Analysis
  - 3.1.5.4. Recent Developments
3.2. Key Strategy Analysis
3.3. Impact of COVID-19 on Key Players

4. Market Segmentation

4.1. Global Women Health Therapeutics Market by Type
- 4.1.1. Infection
- 4.1.2. Pregnancy
- 4.1.3. Oncology
  - 4.1.3.1. Cervical Cancer
  - 4.1.3.2. Uterine Cancer
  - 4.1.3.3. Ovarian Cancer
  - 4.1.3.4. Vaginal &Vular
4.2. Global Women Health Therapeutics Market by End-User
- 4.2.1. Hospital and Clinics
- 4.2.2. Ambulatory Centers

5. Regional Analysis

5.1. North America
- 5.1.1. US
- 5.1.2. Canada
5.2. Europe
- 5.2.1. UK
- 5.2.2. Germany
- 5.2.3. Italy
- 5.2.4. Spain
- 5.2.5. France
- 5.2.6. Rest of Europe
5.3. Asia-Pacific
- 5.3.1. China
- 5.3.2. India
- 5.3.3. Japan
- 5.3.4. South Korea
- 5.3.5. Rest of Asia-Pacific
5.4. Rest of the World

6. Company Profiles

6.1. Airgas, Ltd.
6.2. Allergan PLC
6.3. Amgen Inc.
6.4. Astellas Pharma Inc.
6.5. Bayer AG
6.6. Eli Lilly and Co
6.7. ICON PLC
6.8. Merck KGaA
6.9. Mithra Pharmaceuticals S.A.
6.10. Novo Nordisk A/S
6.11. Pfizer Inc.
6.12. Oasmia Pharmaceutical AB
6.13. ObsEva SA
6.14. Radius Health, Inc.
6.15. Sanofi SA
6.16. Takeda Pharmaceutical Co. Ltd.
6.17. Teva Pharmaceuticals Industries Ltd.
6.18. Tsumura & Co.Arkema S.A.